Company Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases.
The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer.
Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus.
CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy.
The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
| Country | United States |
| IPO Date | Dec 8, 1983 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Geert R. Kersten Esq. |
Contact Details
Address: 8229 Boone Boulevard Vienna, Virginia United States | |
| Website | https://cel-sci.com |
Stock Details
| Ticker Symbol | CVM |
| Exchange | AMEX |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000725363 |
| CUSIP Number | 150837607 |
| ISIN Number | US1508376076 |
| Employer ID | 84-0916344 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Geert R. Kersten Esq. | Chief Executive Officer, Treasurer & Director |
| Dr. Daniel H. Zimmerman Ph.D. | Senior Vice President of Research & Cellular Immunology |
| Dr. Eyal Talor Ph.D. | Chief Scientific Officer |
| Dr. Giovanni Selvaggi M.D. | Acting Chief Medical Officer |
| John Cipriano | Senior Vice President of Regulatory Affairs |
| Patricia B. Prichep | Chief Financial and Operations Officer & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 30, 2024 | S-3/A | [Amend] Filing |
| Oct 25, 2024 | S-3 | Filing |
| Oct 11, 2024 | POS AM | Filing |
| Oct 10, 2024 | AW | Filing |
| Oct 08, 2024 | S-3/A | [Amend] Filing |
| Oct 01, 2024 | 4 | Filing |
| Oct 01, 2024 | 4 | Filing |
| Oct 01, 2024 | 4 | Filing |